Short answer
Insmed Incorporated (INSM) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $142M (up 52.4% year over year) with net income of −$370M.
Q3 2025 key financials · XBRL
- Revenue
- $142M
- +52.4% YoY · +32.5% QoQ
- Net income
- −$370M
- −67.8% YoY · −15.0% QoQ
- Operating margin
- -257.1%
- EPS (diluted)
- −$1.77
- −41.6% YoY · −4.1% QoQ
Source: XBRL data from the Insmed Incorporated (INSM) Q3 2025 10-Q on SEC EDGAR. USD.
Insmed Incorporated Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Commercialization dependency on BRINSUPRI launched Q3 2025 in US with required regulatory approvals outside US
- Most material update: Medicare reimbursement pressure from IRA potential impact on BRINSUPRI pricing and profitability
- Impactful regulatory risk: Approval delays or denials in key markets including US, EU, Japan for ARIKAYCE front-line, BRINSUPRI, or brensocatib
- Near-term operational risk: Building and maintaining effective sales and marketing capability for ARIKAYCE, BRINSUPRI in multiple regions
- Financial risk: Revenue reversals from price refunds in France and 9.4% ARIKAYCE price cut in Japan in 2023 affecting financial results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insmed Incorporated quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.